早产儿视网膜病变抗血管内皮生长因子药物治疗新进展

New advances in anti-vascular endothelial growth factor drug therapy for retinopathy of prematurity

早产儿视网膜病变(retinopathy of prematurity,ROP)是一种进行性视网膜血管异常生长、病理性新生血管形成的致盲性眼病。传统一线治疗激光光凝,存在治疗相对滞后、不可逆周边视野缺损等局限性。近年来,以哌加他尼钠、贝伐单抗、雷珠单抗、阿柏西普和康柏西普等为代表的抗血管内皮生长因子药物已广泛用于眼底新生血管性疾病,尤其在ROP治疗中不断取得新的进展,并成为其基础和临床研究的焦点和热点。

Retinopathy of prematurity（ ROP） is one kind of blinding ophthalmopathy with progressive retinal vascular grow th and pathological neovascularization.Traditional first-line treatment of laser photocoagulation has limitations such as relatively delayed treatment and irreversible peripheral visual field defects. In recent years,anti-vascular endothelial grow th factor drugs including pegaptanib sodium,bevacizumab,ranibizumab,aflibercept and conbercept have been widely used in fundus neovascular diseases,and especially new progress has been made in the treatment of R O P,and it has become the focus and hotspot of its basic and clinical research.